Report cover image

Global Meningococcal Group A and C Conjugate Vaccine Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 72 Pages
SKU # APRC20340207

Description

Summary

According to APO Research, The global Meningococcal Group A and C Conjugate Vaccine market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Meningococcal Group A and C Conjugate Vaccine include GSK, Pfizer, Sanofi Pasteur and Chongqing Zhifei Biological Products, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Meningococcal Group A and C Conjugate Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Group A and C Conjugate Vaccine.

The Meningococcal Group A and C Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Meningococcal Group A and C Conjugate Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Meningococcal Group A and C Conjugate Vaccine Segment by Company

GSK
Pfizer
Sanofi Pasteur
Chongqing Zhifei Biological Products
Meningococcal Group A and C Conjugate Vaccine Segment by Type

Prefilled
Non-prefilled
Meningococcal Group A and C Conjugate Vaccine Segment by Application

Adults
Children
Meningococcal Group A and C Conjugate Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Group A and C Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Group A and C Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Group A and C Conjugate Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Meningococcal Group A and C Conjugate Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Meningococcal Group A and C Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

72 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Estimates and Forecasts (2020-2031)
1.3 Meningococcal Group A and C Conjugate Vaccine Market by Type
1.3.1 Prefilled
1.3.2 Non-prefilled
1.4 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Type
1.4.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size Overview by Type (2020-2031)
1.4.2 Global Meningococcal Group A and C Conjugate Vaccine Historic Market Size Review by Type (2020-2025)
1.4.3 Global Meningococcal Group A and C Conjugate Vaccine Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Type (2020-2025)
1.5.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Type (2020-2025)
1.5.4 South America Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Meningococcal Group A and C Conjugate Vaccine Industry Trends
2.2 Meningococcal Group A and C Conjugate Vaccine Industry Drivers
2.3 Meningococcal Group A and C Conjugate Vaccine Industry Opportunities and Challenges
2.4 Meningococcal Group A and C Conjugate Vaccine Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Meningococcal Group A and C Conjugate Vaccine Revenue (2020-2025)
3.2 Global Top Players by Meningococcal Group A and C Conjugate Vaccine Sales (2020-2025)
3.3 Global Top Players by Meningococcal Group A and C Conjugate Vaccine Price (2020-2025)
3.4 Global Meningococcal Group A and C Conjugate Vaccine Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Meningococcal Group A and C Conjugate Vaccine Major Company Production Sites & Headquarters
3.6 Global Meningococcal Group A and C Conjugate Vaccine Company, Product Type & Application
3.7 Global Meningococcal Group A and C Conjugate Vaccine Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Meningococcal Group A and C Conjugate Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Meningococcal Group A and C Conjugate Vaccine Players Market Share by Revenue in 2024
3.8.3 2023 Meningococcal Group A and C Conjugate Vaccine Tier 1, Tier 2, and Tier 3
4 Meningococcal Group A and C Conjugate Vaccine Regional Status and Outlook
4.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Meningococcal Group A and C Conjugate Vaccine Historic Market Size by Region
4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales in Volume by Region (2020-2025)
4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales in Value by Region (2020-2025)
4.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Meningococcal Group A and C Conjugate Vaccine Forecasted Market Size by Region
4.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales in Volume by Region (2026-2031)
4.3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales in Value by Region (2026-2031)
4.3.3 Global Meningococcal Group A and C Conjugate Vaccine Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Meningococcal Group A and C Conjugate Vaccine by Application
5.1 Meningococcal Group A and C Conjugate Vaccine Market by Application
5.1.1 Adults
5.1.2 Children
5.2 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Application
5.2.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size Overview by Application (2020-2031)
5.2.2 Global Meningococcal Group A and C Conjugate Vaccine Historic Market Size Review by Application (2020-2025)
5.2.3 Global Meningococcal Group A and C Conjugate Vaccine Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Application (2020-2025)
5.3.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Application (2020-2025)
5.3.4 South America Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 GSK
6.1.1 GSK Comapny Information
6.1.2 GSK Business Overview
6.1.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.1.5 GSK Recent Developments
6.2 Pfizer
6.2.1 Pfizer Comapny Information
6.2.2 Pfizer Business Overview
6.2.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.2.5 Pfizer Recent Developments
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Comapny Information
6.3.2 Sanofi Pasteur Business Overview
6.3.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments
6.4 Chongqing Zhifei Biological Products
6.4.1 Chongqing Zhifei Biological Products Comapny Information
6.4.2 Chongqing Zhifei Biological Products Business Overview
6.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.4.5 Chongqing Zhifei Biological Products Recent Developments
7 North America by Country
7.1 North America Meningococcal Group A and C Conjugate Vaccine Sales by Country
7.1.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2020-2025)
7.1.3 North America Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2026-2031)
7.2 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country
7.2.1 North America Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country (2020-2025)
7.2.3 North America Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country
8.1.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2020-2025)
8.1.3 Europe Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2026-2031)
8.2 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country
8.2.1 Europe Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country (2020-2025)
8.2.3 Europe Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Country
9.1.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Country (2020-2025)
9.1.3 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Market Size by Country
9.2.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Meningococcal Group A and C Conjugate Vaccine Sales by Country
10.1.1 South America Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2020-2025)
10.1.3 South America Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2026-2031)
10.2 South America Meningococcal Group A and C Conjugate Vaccine Market Size by Country
10.2.1 South America Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Meningococcal Group A and C Conjugate Vaccine Market Size by Country (2020-2025)
10.2.3 South America Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country
11.1.1 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (2020-2025)
11.1.3 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size by Country
11.2.1 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Meningococcal Group A and C Conjugate Vaccine Value Chain Analysis
12.1.1 Meningococcal Group A and C Conjugate Vaccine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Meningococcal Group A and C Conjugate Vaccine Production Mode & Process
12.2 Meningococcal Group A and C Conjugate Vaccine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Meningococcal Group A and C Conjugate Vaccine Distributors
12.2.3 Meningococcal Group A and C Conjugate Vaccine Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.